Biotheranostics was acquired by Hologic in February 2021, and continues to offer its portfolio of proprietary genomic assays to support personalized disease management in oncology.

Biotheranostics announces the inclusion of Breast Cancer Index in the ASCO ® Clinical Practice Guideline to help guide extended endocrine therapy decisions. Click here to learn more.

Hologic has now acquired Biotheranostics, developer of two highly differentiated molecular diagnostic tests for breast and metastatic cancers – Breast Cancer Index™ (BCI) and CancerTYPE ID® (CTID).

Oct 2, 2025 · NeoGenomics has partnered with Biotheranostics, a Hologic Company, to make ordering BCI easy for women with early-stage hormone receptor-positive (HR+) breast cancer.

Biotheranostics is a molecular diagnostics company that develops and provides diagnostic, prognostic, and predictive tests that helps physicians in the treatment of cancer patients.

Aug 30, 2024 · Biotheranostics is a field at the intersection of biology, therapy, and diagnostics, focusing on using advanced molecular diagnostics to guide personalized treatment for cancer patients.

Information on acquisition, funding, cap tables, investors, and executives for Biotheranostics. Use the PitchBook Platform to explore the full profile.

The Breast Cancer Index ® (BCI™) test, performed by Biotheranostics, Inc., is the only guideline-recognized test to predict which early-stage, HR+ patients are likely to benefit from extended …

Biotheranostics, Inc. has been acquired by Hologic. Hologic is an innovative medical technology company whose purpose is to enable healthier lives everywhere, every day.

Mar 19, 2025 · BioTheranostics develops and commercializes proprietary molecular-based diagnostic, prognostic, and predictive tests that provide physicians with actionable information to help to guide …